Growth strategy through partnerships

A robust growth strategy is important for a fast developing specialty biopharmaceutical company. Through strategic in-licensing and productive academic collaborations, ObsEva is building a portfolio of products and product candidates for women’s reproductive health that can address significant unmet medical needs for millions of women worldwide.

At ObsEva, our growth strategy includes..

At ObsEva, our growth strategy includes the acquisition of additional novel clinical-stage assets that can address unmet needs for our patients. Clinical-stage assets of interest for ObsEva would meet the following criteria:

  • Women’s reproductive health medicine
  • Small chemical molecules, peptides, proteins, or mAbs
  • Development stage: close to First-In-Man up to end-of-Phase2
  • License rights: preferably global

Collaboration with Kissei Pharmaceutical

In 2015, ObsEva entered into a collaboration agreement with Kissei Pharmaceutical Co., Ltd., a Japanese pharmaceutical company with approximately 70 years of expertise in the fields of obstetrics/gynecology, renal dialysis, urology, metabolism, and ophthalmology.

Under the terms of the agreement, ObsEva acquired the exclusive license to develop and commercialize Linzagolix worldwide (excluding certain Asian countries) for the treatment of uterine fibroids, endometriosis and other possible indications.


Get in touch for partnering

Should you represent a pharmaceutical company seeking a strong and committed partner for the development and the commercialization of a potential product, please do not hesitate to send an email to the contact below briefly describing your project.


Read our privacy policy here.